Literature DB >> 33235369

The screening imperative for multiple myeloma.

S Vincent Rajkumar.   

Abstract

Entities:  

Keywords:  Cancer; Health care; Therapeutics

Year:  2020        PMID: 33235369     DOI: 10.1038/d41586-020-03227-y

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  4 in total

1.  Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey.

Authors:  O Landgren; B I Graubard; J A Katzmann; R A Kyle; I Ahmadizadeh; R Clark; S K Kumar; A Dispenzieri; A J Greenberg; T M Therneau; L J Melton; N Caporaso; N Korde; M Roschewski; R Costello; G M McQuillan; S V Rajkumar
Journal:  Leukemia       Date:  2014-01-20       Impact factor: 11.528

2.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Authors:  María-Victoria Mateos; Miguel-Teodoro Hernández; Pilar Giraldo; Javier de la Rubia; Felipe de Arriba; Lucía López Corral; Laura Rosiñol; Bruno Paiva; Luis Palomera; Joan Bargay; Albert Oriol; Felipe Prosper; Javier López; Eduardo Olavarría; Nuria Quintana; José-Luis García; Joan Bladé; Juan-José Lahuerta; Jesús-F San Miguel
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

3.  Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.

Authors:  Sagar Lonial; Susanna Jacobus; Rafael Fonseca; Matthias Weiss; Shaji Kumar; Robert Z Orlowski; Jonathan L Kaufman; Abdulraheem M Yacoub; Francis K Buadi; Timothy O'Brien; Jeffrey V Matous; Daniel M Anderson; Robert V Emmons; Anuj Mahindra; Lynne I Wagner; Madhav V Dhodapkar; S Vincent Rajkumar
Journal:  J Clin Oncol       Date:  2019-10-25       Impact factor: 44.544

4.  Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey.

Authors:  O Landgren; B I Graubard; S Kumar; R A Kyle; J A Katzmann; K Murata; R Costello; A Dispenzieri; N Caporaso; S Mailankody; N Korde; M Hultcrantz; T M Therneau; D R Larson; J R Cerhan; S V Rajkumar
Journal:  Blood Cancer J       Date:  2017-10-20       Impact factor: 11.037

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.